EMA's CHMP Recommends the Approval of Two Bevacizumab Biosimilars
Shots:
- The EMA’s CHMP has adopted the positive opinion recommending the approval of two biosimilar bevacizumab medicines- Alymsys and Oyavas for the treatment of carcinoma of the colon or rectum- breast cancer- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
- Mabxience’s Alymsys and STADA’s Oyavas both show comparable quality- safety & efficacy to Avastin (bevacizumab)
- Oyavas and Alymsys will be available as 25 mg/ml concentrate for solution for infusion
Source 1- Source 2
Ref: EMA | Image: Europa EU
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com